GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global lentivirus CDMO ...

ROCHESTER, Minn., December 16, 2025--100% of mice treated with a single intravenous dose of VV169 saw complete clearance of ...

Lentiviral vectors are increasingly popular as gene delivery tools for cell and gene therapies. Their value has been demonstrated within CAR-T and TCR therapies for blood malignancies that don’t ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

The expansion of LENTIVERSE™ platform introduces "One Lentiviral Vector Platform, Two Paths to Advance Cures," aligning scientific rigor with transparent economics and global accessibility.

The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is becoming of higher importance. Lentiviruses are enveloped viruses that are rather ...

Viral vectors are indispensable tools for advancing gene therapy discovery and development. As researchers progress towards clinically relevant processes, scaling up production and clarification of ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral ...